Whitley N O, Mirvis S E
Department of Diagnostic Radiology, University of Maryland Hospital, Baltimore.
Crit Rev Diagn Imaging. 1989;29(2):103-16.
Small cell carcinoma of the lung (SCCL) is a fulminant disease process with early extrathoracic dissemination. Surgery for cure has generally been abandoned and combined chemotherapy is the treatment of choice. The staging of SCCL is designed to identify areas of involvement for (1) comparison of therapeutic techniques, (2) prognostic determinations, (3) determination of sites of disease to use for assessment of response, and (4) for determination of areas that may require additional local therapy such as radiation or surgery. The staging evaluation, therefore, is designed to evaluate the extent of extrathoracic disease rather than just the presence of chest involvement. CT scanning has made a valuable contribution to the delineation of intrathoracic and metastatic disease and is now included in the staging workup of patients with SCCL since metastatic involvement of the liver, bone, bone marrow, CNS, and adrenal glands is common.
肺小细胞癌（SCCL）是一种具有早期胸外播散的暴发性疾病过程。根治性手术通常已被放弃，联合化疗是首选治疗方法。SCCL的分期旨在确定受累区域，用于（1）比较治疗技术，（2）判断预后，（3）确定用于评估反应的疾病部位，以及（4）确定可能需要额外局部治疗（如放疗或手术）的区域。因此，分期评估旨在评估胸外疾病的范围，而不仅仅是胸部受累情况。CT扫描对胸内和转移性疾病的描绘做出了重要贡献，由于肝、骨、骨髓、中枢神经系统和肾上腺的转移受累很常见，现在已被纳入SCCL患者的分期检查中。
